| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.3 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |